Agenus Inc. Stock News

Find out what pushed them up to see if the good times can keep rolling.

LEXINGTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines design

Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, N

Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.

Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt.

Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.

The biotech announced a big licensing deal with Bristol Myers Squibb.

Biotech penny stocks continue to heat up; here's 4 under $5 to look into The post Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News

Bristol-Myers Squibb Co (NYSE: BMY) and Agenus Inc (NASDAQ: AGEN) have entered into a global exclusive license agreement, under which Bristol Myers will receive an exclusive license to Agenus' AGE

The stock price of Agenus Inc (NASDAQ: AGEN) increased by over 30% pre-market. This is why it happened.

Conference Call on Tuesday, May 18, 2021 at 8:30 a.m. ET Conference Call on Tuesday, May 18, 2021 at 8:30 a.m. ET

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts ap

The company announced mixed Q1 results on a day when many biotech stocks were sinking.

Agenus ' (AGEN) CEO Garo Armen on Q1 2021 Results - Earnings Call Transcript